Replies to post #631362 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Amazing!!! That post was nine years ago!

[dstock07734]

https://investorshub.advfn.com/boards/replies.aspx?msg=104877151
Here is the reason I feel it is amazing.

Just take a look at the leadership. You don't need imagination to know what it means.
https://www.asterinsights.com/company/leadership/

M2Gen® was created by Moffitt Cancer Center in 2006 as a service company to operationalize a groundbreaking five-year, $150 million collaboration in personalized medicine between Moffitt and Merck. From that beginning, M2Gen has developed informatics and R&D solutions that provide an intelligence-rich system for rapid drug discovery and development.

https://thenationalmdsstudy.net/moffitt

https://www.cdr-inc.com/news/press-release/cdr-merck-ghi-and-mckesson-ventures-invest-innovative-oncology-data-and

M2GEN today announced a significant new investment by Clayton, Dubilier & Rice (“CD&R”) funds, the Merck Global Health Innovation Fund (“Merck GHI”), and McKesson Ventures to recapitalize M2GEN, a leading oncology data and informatics platform focused on transforming cancer care, in partnership with its existing shareholders. The financial terms of the transaction, which closed today, were not disclosed.

Merck GHI and McKesson Ventures invested alongside CD&R funds, collectively now the company’s largest shareholder. Existing shareholders Moffitt Cancer Center, Hearst Healthcare, and The Ohio State University Foundation continue to hold a significant minority interest M2GEN. Proceeds from the transaction are expected to accelerate growth of M2GEN’s consented, linked clinical and genomic data asset and advance the technology and informatics capabilities of the company. In conjunction with the recapitalization, Sandra E. Peterson, CD&R Operating Partner and former Group Worldwide Chairman of Johnson & Johnson, has assumed the role of Chair of the M2GEN board.